Incidence and Features of SARS-CoV-2 Breakthrough Infection in the Hematological Conditions After Tixagevimab-Cilgavimab Prophylaxis

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA(2023)

Cited 0|Views29
No score
Key words
IBCL, SARS-CoV-2, tixagevimab-cilgavimab, breakthrough infection, hematological diseases, prophylaxis, immunocompromised patients, case
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined